Immunoglobulin A (IgA) plays a key role in defending mucosal surfaces against attack by
infectious microorganisms. Such sites present a major site of susceptibility due to their vast …

Immunoglobulin A (IgA) is the most abundant antibody class present at mucosal surfaces.
The production of IgA exceeds the production of all other antibodies combined, supporting …

Over the last decades, cancer immunotherapies such as checkpoint blockade and adoptive
T cell transfer have been a game changer in many aspects and have improved the treatment …

Therapeutic monoclonal antibodies (mAbs) have become one of the fastest growing classes
of drugs in recent years and are approved for the treatment of a wide range of indications …

Antibody therapy of cancer is increasingly used in the clinic and has improved patient's life
expectancy. Except for immune checkpoint inhibition, the mode of action of many antibodies …

Mucosal surfaces constitute the frontiers of the body and are the biggest barriers of our body
for the outside world. Immunoglobulin A (IgA) is the most abundant antibody class present at …

Therapeutic monoclonal antibodies (mAb), directed toward either tumor antigens or
inhibitory checkpoints on immune cells, are effective in cancer therapy. Increasing evidence …

Interactions between the Fc segment of IgG and its receptors (FcγRs) found on cells such as
natural killer cells, monocytes, macrophages and neutrophils can potentially mediate …

Background: Extensive efforts have been made in optimizing monoclonal immunoglobulin
(Ig) G antibodies for use in clinical practice. Accumulating evidence suggests that IgA or anti …

Compared to the evolutionary diversity of antibody isotypes, the spectrum of currently
approved therapeutic antibodies is biased to the human IgG1 isotype. Detailed studies into …